{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:11:17Z","timestamp":1789668677067,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2024YFC2510301"],"award-info":[{"award-number":["2024YFC2510301"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2025YFC3508504"],"award-info":[{"award-number":["2025YFC3508504"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["YW2025-014"],"award-info":[{"award-number":["YW2025-014"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271834"],"award-info":[{"award-number":["82271834"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572047"],"award-info":[{"award-number":["82572047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC22024245"],"award-info":[{"award-number":["SHDC22024245"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai City Science and Technology Commission","doi-asserted-by":"publisher","award":["25TS1405100"],"award-info":[{"award-number":["25TS1405100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai City Science and Technology Commission","doi-asserted-by":"publisher","award":["23Y11905000"],"award-info":[{"award-number":["23Y11905000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.semarthrit.2026.152958","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:23:58Z","timestamp":1772781838000},"page":"152958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic effect of tofacitinib combined with leflunomide for refractory Takayasu arteritis: pilot study"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-2105","authenticated-orcid":false,"given":"Shuwai","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-6517","authenticated-orcid":false,"given":"Xiufang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6718-4959","authenticated-orcid":false,"given":"Jiayu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2616-5810","authenticated-orcid":false,"given":"Huimin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-7788","authenticated-orcid":false,"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152958_bib0001","series-title":"Takayasu arteritis","author":"Trinidad","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0002","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejim.2023.02.027","article-title":"Predictors of relapse in Takayasu arteritis","volume":"111","author":"He","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0003","article-title":"Takayasu Arteritis: JACC Focus Seminar 3\/4","author":"Joseph","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152958_bib0004","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1007\/s10067-021-05743-2","article-title":"Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis","volume":"40","author":"Misra","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-med-060622-100940","article-title":"New therapeutic approaches to large-vessel vasculitis","volume":"75","author":"Kaymakci","year":"2024","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.152958_bib0006","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152958_bib0007","first-page":"975","article-title":"Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis","volume":"41","author":"Marvisi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0008","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13075-020-02311-y","article-title":"Tocilizumab in treatment-na\u00efve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial","volume":"22","author":"Mekinian","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152958_bib0009","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152958_bib0010","doi-asserted-by":"crossref","first-page":"rkaf013","DOI":"10.1093\/rap\/rkaf013","article-title":"Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis","volume":"9","author":"Yoshifuji","year":"2025","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf286","article-title":"Baricitinib for Takayasu arteritis refractory to TNF-\u03b1 inhibitors: a multi-centre, single-arm trial","author":"Li","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0012","series-title":"Leflunomide","author":"Padda","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0013","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.trsl.2022.12.004","article-title":"A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta","volume":"255","author":"Dai","year":"2023","journal-title":"Transl Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152958_bib0014","first-page":"69","article-title":"The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis","volume":"124","author":"Cui","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103277","article-title":"Pro-fibrotic effect of the susceptible gene PCSK5 in vascular fibrosis of Takayasu arteritis via TGF-\u03b2 and SMAD3 signaling pathway activation","volume":"148","author":"Wang","year":"2024","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","article-title":"Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort","volume":"50","author":"Cui","year":"2020","journal-title":"Semin Arthrit Rheum"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20930114","article-title":"Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study","volume":"12","author":"Ying","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152958_bib0018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03009742.2011.633553","article-title":"Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study","volume":"41","author":"de Souza","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003992","article-title":"Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study","volume":"10","author":"Peron Filho","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0020","series-title":"Tofacitinib","author":"Padda","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0021","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.2147\/JIR.S369963","article-title":"Biomarker changes and molecular signatures associated with Takayasu Arteritis following treatment with glucocorticoids and Tofacitinib","volume":"15","author":"Dai","year":"2022","journal-title":"J Inflamm Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study","volume":"55","author":"Wang","year":"2022","journal-title":"Semin Arthrit Rheum"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109794","article-title":"Exploration of molecular signatures associated with different clinical features of Takayasu arteritis based on a prospective cohort study","volume":"256","author":"Kong","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2022.08.058","article-title":"Biomarkers in Takayasu arteritis","volume":"371","author":"Wen","year":"2023","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152958_bib0026","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/ard-2022-223482","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0028","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-024-03314-9","article-title":"Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature","volume":"26","author":"Loricera","year":"2024","journal-title":"Arthrit Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00002281-199701000-00003","article-title":"Differences in clinical presentation and outcome in different countries for Takayasu's arteritis","volume":"9","author":"Numano","year":"1997","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152958_bib0030","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2010.10.002","article-title":"Evaluation of Takayasu arteritis activity by delayed contrast-enhanced magnetic resonance imaging","volume":"155","author":"Jiang","year":"2012","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152958_bib0031","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s10067-022-06113-2","article-title":"Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review","volume":"41","author":"Xue","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211020917","article-title":"Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review","volume":"13","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152958_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101969","article-title":"Genetics of vasculitis","volume":"38","author":"Gonz\u00e1lez-Gay","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0034","article-title":"Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy","volume":"7","author":"Carmona","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152958_bib0035","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/endrev\/bnad016","article-title":"Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?","volume":"44","author":"Pofi","year":"2023","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152958_bib0036","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","article-title":"Regulation of B cell function by the immunosuppressive agent leflunomide","volume":"61","author":"Siemasko","year":"1996","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.152958_bib0037","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/j.transproceed.2016.07.052","article-title":"Inhibition of JAK3 and PKC via immunosuppressive drugs Tofacitinib and Sotrastaurin inhibits proliferation of Human B lymphocytes In vitro","volume":"48","author":"Martina","year":"2016","journal-title":"Transplant Proc"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152958_bib0038","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro","volume":"73","author":"Wang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087986","article-title":"JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis","volume":"14","author":"Frede","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152958_bib0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/1744666X.2019.1624527","article-title":"Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sj\u00f6gren's syndrome","volume":"15","author":"van der Heijden","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0041","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13075-025-03523-w","article-title":"Single-cell transcriptome analysis reveals cellular heterogeneity in the aortas of Takayasu arteritis","volume":"27","author":"Gao","year":"2025","journal-title":"Arthrit Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152958_bib0042","first-page":"870","article-title":"Characteristics of B cells and immunoglobulin profile in Takayasu's arteritis","volume":"41","author":"Ci","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152958_bib0043","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00296-019-04390-w","article-title":"Refractory Takayasu arteritis successfully treated with rituximab: case-based review","volume":"39","author":"Mutoh","year":"2019","journal-title":"Rheumatol Int"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152958_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126528","article-title":"A glimpse into humoral response and related therapeutic approaches of Takayasu's arteritis","volume":"25","author":"Guo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217313","article-title":"Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant","volume":"2017","author":"O'Connor","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152958_bib0046","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/rheumatology\/kex249","article-title":"Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature","volume":"57","author":"Pazzola","year":"2018","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2026.152958_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2025.102060","article-title":"Update in imaging for large vessel vasculitis","author":"Nielsen","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152958_bib0048","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.reuma.2017.07.020","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.152958_bib0049","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.152958_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082197","article-title":"Cancer risk in patients treated with the JAK inhibitor Tofacitinib: systematic review and meta-analysis","volume":"15","author":"Bezzio","year":"2023","journal-title":"Cancer (Basel)"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152958_bib0051","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1038\/s41467-023-38753-6","article-title":"Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase","volume":"14","author":"Zhan","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152958_bib0052","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2018.01.107","article-title":"Leflunomide: A promising drug with good antitumor potential","volume":"496","author":"Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"SI","key":"10.1016\/j.semarthrit.2026.152958_bib0053","doi-asserted-by":"crossref","first-page":"SI4","DOI":"10.1093\/rheumatology\/keab644","article-title":"PET in Takayasu arteritis: onwards and upwards towards a future of robust multimodality disease activity assessment?","volume":"61","author":"Campochiaro","year":"2022","journal-title":"Rheumatol (Oxf)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:56:23Z","timestamp":1789667783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"alternative-id":["S0049017226000478"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152958","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effect of tofacitinib combined with leflunomide for refractory Takayasu arteritis: pilot study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152958"}}